Literature DB >> 19002391

Risk factors of long-term incidences of thrombosis, myelofibrosis and evolution into malignance in polycythemia vera: a single center experience from China.

Jie Bai1, Yangping Xue1, Lei Ye1, Jianfeng Yao1, Chunlin Zhou1, Zonghong Shao1, Linsheng Qian1, Renchi Yang1, Haiyan Li1, Hongyun Zhang1, Yizhou Zheng2.   

Abstract

To find out risk factors of incidences of long-term complications of thrombosis, myelofibrosis with myeloid metaplasia (MMM) and evolution into malignance in Chinese PV patients, we evaluated 320 PV patients referred to our center from April 1984 to June 2005 by Kaplan-Meier estimation and Cox proportional hazards models. A total of 250 events of thrombosis were observed in 138 (43.13%) patients. Advanced age, prior thrombosis and hemoglobin out of control were statistically significant risk factors of incidences of thrombotic events. A total of 43 patients progressed into MMM at a median time of 84 (7-240) months, higher white blood cell (WBC) count, splenomegaly, receiving alkylating agent and hydroxycarbamide were associated with the progression into MMM. During the follow-up time, 11 and 2 patients died of fatal complications of thrombosis and acute myeloid leukaemia (AML), respectively. These results suggest that advanced age, prior thrombosis and hemoglobin out of control contributed to relatively high incidence of thromboembolism; higher WBC count, splenomegaly, receiving alkylating agent and hydroxycarbamide were risk factors of evolution to MMM. The main poor factors that influenced the survival of Chinese PV patients were incidences of thromboembolism and evolution into AML.

Entities:  

Mesh:

Year:  2008        PMID: 19002391     DOI: 10.1007/s12185-008-0188-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  17 in total

1.  Complications and causes of death in polycythaemia vera.

Authors:  E CHIEVITZ; T THIEDE
Journal:  Acta Med Scand       Date:  1962-11

2.  Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.

Authors:  Y Najean; J D Rain
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

Review 3.  The very long-term evolution of polycythemia vera: an analysis of 318 patients initially treated by phlebotomy or 32P between 1969 and 1981.

Authors:  Y Najean; J D Rain
Journal:  Semin Hematol       Date:  1997-01       Impact factor: 3.851

Review 4.  Interferon alpha in the treatment of polycythemia vera.

Authors:  E Lengfelder; U Berger; R Hehlmann
Journal:  Ann Hematol       Date:  2000-03       Impact factor: 3.673

5.  High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.

Authors:  Jean-Jacques Kiladjian; Bruno Cassinat; Pascal Turlure; Nathalie Cambier; Murielle Roussel; Sylvia Bellucci; Marie-Laurence Menot; Gerald Massonnet; Jean-Luc Dutel; Kamel Ghomari; Philippe Rousselot; Marie-Jose Grange; Yasmina Chait; William Vainchenker; Nathalie Parquet; Lina Abdelkader-Aljassem; Jean-François Bernard; Jean-Didier Rain; Sylvie Chevret; Christine Chomienne; Pierre Fenaux
Journal:  Blood       Date:  2006-05-18       Impact factor: 22.113

6.  Acute leukaemia after hydroxyurea therapy in polycythaemia vera and allied disorders: prospective study of efficacy and leukaemogenicity with therapeutic implications.

Authors:  A Weinfeld; B Swolin; J Westin
Journal:  Eur J Haematol       Date:  1994-03       Impact factor: 2.997

7.  Polycythaemia vera in young people: an analysis of 58 cases diagnosed before 40 years.

Authors:  Y Najean; P Mugnier; C Dresch; J D Rain
Journal:  Br J Haematol       Date:  1987-11       Impact factor: 6.998

8.  Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia.

Authors:  Francesco Passamonti; Lucia Malabarba; Ester Orlandi; Claudia Baratè; Angelo Canevari; Ercole Brusamolino; Maurizio Bonfichi; Luca Arcaini; Sabrina Caberlon; Cristiana Pascutto; Mario Lazzarino
Journal:  Haematologica       Date:  2003-01       Impact factor: 9.941

9.  Efficacy and safety of low-dose aspirin in polycythemia vera.

Authors:  Raffaele Landolfi; Roberto Marchioli; Jack Kutti; Heinz Gisslinger; Gianni Tognoni; Carlo Patrono; Tiziano Barbui
Journal:  N Engl J Med       Date:  2004-01-08       Impact factor: 91.245

10.  Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols.

Authors:  P D Berk; J D Goldberg; P B Donovan; S M Fruchtman; N I Berlin; L R Wasserman
Journal:  Semin Hematol       Date:  1986-04       Impact factor: 3.851

View more
  4 in total

1.  Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis.

Authors:  Alessandra Carobbio; Alberto Ferrari; Arianna Masciulli; Arianna Ghirardi; Giovanni Barosi; Tiziano Barbui
Journal:  Blood Adv       Date:  2019-06-11

2.  Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis.

Authors:  Alberto Ferrari; Alessandra Carobbio; Arianna Masciulli; Arianna Ghirardi; Guido Finazzi; Valerio De Stefano; Alessandro Maria Vannucchi; Tiziano Barbui
Journal:  Haematologica       Date:  2019-05-23       Impact factor: 9.941

3.  Volumetric Splenomegaly in Patients With Polycythemia Vera.

Authors:  Myung-Won Lee; Sang-Hoon Yeon; Hyewon Ryu; Ik-Chan Song; Hyo-Jin Lee; Hwan-Jung Yun; Seon Young Kim; Jeong Eun Lee; Kyung Sook Shin; Deog-Yeon Jo
Journal:  J Korean Med Sci       Date:  2022-03-21       Impact factor: 2.153

4.  Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.

Authors:  Neslihan Andıç; Mustafa Ünübol; Eren Yağcı; Olga Meltem Akay; İrfan Yavaşoğlu; Vefki Gürhan Kadıköylü; Ali Zahit Bolaman
Journal:  Turk J Haematol       Date:  2016-04-18       Impact factor: 1.831

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.